Drug policy impacts regional trends of ezetimibe use

Drug policy impacts regional trends of ezetimibe use

(HealthDay)—Within Canada, regional variation has been noted in ezetimibe use, which is associated with the restrictiveness of publicly-funded drug formularies, according to a study published online June 3 in Circulation: Cardiovascular Quality and Outcomes.

Lingyun Lu, Pharm.D., from the Western University of Health Sciences in Pomona, Calif., and colleagues conducted a population-level cohort study to examine ezetimibe use in four provinces in Canada. The provinces had a gradient in the restrictiveness of ezetimibe in publicly-funded formularies (most to least restrictive: British Columbia, Alberta, Quebec, and Ontario). Use was examined using IMS Health Canada's data from June 2003 to December 2012.

The researchers observed in ezetimibe use patterns. The lowest monthly increasing rate was seen in British Columbia (most restrictive), which increased from $261 (Canadian dollars) to $21,926 from June 2003 to December 2012 ($190/100,000 population/month). In contrast, the least restrictive Ontario had the most rapid monthly increase, from $223 to $74,030 ($647/100,000 population/month). Quebec and Alberta had intermediate increases, from $130 to $59,690 ($522/100,000 population/month) and from $356 to $37,604 ($327/100,000 population/month), respectively.

"Ezetimibe use remains common, increasing during the past decade," the authors write. "The gradient in use was related to variability in restrictiveness of the provincial formularies, illustrating the potential of a policy response gradient that may be used to more effectively manage medication use."

Several authors disclosed financial ties to the pharmaceutical, medical device, and insurance industries.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Evolocumab superior to ezetimibe in lowering LDL cholesterol

Mar 31, 2014

Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable ...

Recommended for you

An autoimmune response may contribute to hypertension

19 hours ago

High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease. Inflammation is thought to promote the development of high blood pressure, though it is not clear what triggers ...

Results of RIBS IV trial reported

Sep 16, 2014

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided superior late angiographic results ...

Results of DKCRUSH-VI trial reported

Sep 16, 2014

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial ...

User comments